Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Ransart – page 102

1 856 clinical trials in Ransart, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Ransart at a glance
1 856
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 856 trials in Ransart

Open in trial search

Study of AMG 193 alone and combined with docetaxel for treatment of advanced MTAP-null solid tumors in adult patients

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:AMG 193
  • Sponsor:Amgen Inc.

Demyelination

Not recruiting

Study on the Effectiveness and Safety of Rozanolixizumab for Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOG-AD)

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Rozanolixizumab
  • Sponsor:UCB Biopharma

Endometrial cancer

Not recruiting

Study on Durvalumab, Paclitaxel, Carboplatin, and Olaparib for Patients with Advanced or Recurrent Endometrial Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Cholangiocarcinoma

Not recruiting

Study Comparing Pemigatinib and Gemcitabine Plus Cisplatin for First-Line Treatment in Patients with Unresectable or Metastatic Cholangiocarcinoma with FGFR2 Rearrangement

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Incyte Corp.

Study on BI 1839100 for Reducing Cough in Patients with Idiopathic or Progressive Pulmonary Fibrosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BI 1839100
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study on the Effects of Inhaled Treprostinil for Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil
  • Sponsor:United Therapeutics Corp.

Study of Nous-209 Genetic Vaccine and Pembrolizumab for Patients with Advanced Microsatellite Instability-High Colorectal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:GAD20-209-FSP-A1
  • Sponsor:Nouscom S.r.l.

Study Comparing Chemotherapy with Paclitaxel, Ifosfamide, and Cisplatin versus High-Dose Chemotherapy with Paclitaxel and Drug Combination for Relapsed Germ Cell Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Study on Batoclimab for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Batoclimab
  • Sponsor:Immunovant Sciences GmbH

Study of petosemtamab with pembrolizumab compared to pembrolizumab alone in patients with head and neck cancer who have not received previous treatment for advanced disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Genmab A/S

Study of petosemtamab compared to standard therapy in previously treated patients with metastatic or recurrent head and neck cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Genmab A/S

Study of Sotatercept for Patients with Severe Pulmonary Arterial Hypertension at High Risk of Mortality

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Acceleron Pharma Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Ransart

What the registry says about research in the country

01 Gastroenterology Research

Clinical trials focusing on optimizing treatment strategies for patients with functional dyspepsia and related gastrointestinal conditions. The research explores innovative approaches to medication management, particularly in the context of proton pump inhibitors (PPIs) usage.

  • Medication De-prescribing Strategies
  • Gastrointestinal Health Management
  • Treatment Optimization Studies

This primary care research evaluates different therapeutic approaches for managing heartburn and reflux symptoms, with a particular focus on developing evidence-based deprescribing protocols.

02 Primary Care Innovation

Investigation into novel treatment alternatives for long-term medication management, comparing on-demand therapy approaches with traditional treatment methods in primary care settings.

  • Alternative Treatment Strategies
  • Patient-Centered Care
  • Chronic Medication Management

The research aims to establish more effective and patient-friendly approaches to long-term medication use in primary care practice.

03 Therapeutic Alternatives

Evaluation of alginate-based treatments as alternative therapeutic options for gastrointestinal conditions, focusing on their potential role in medication transition strategies.

  • Comparative Effectiveness Research
  • Alternative Medicine Approaches
  • Treatment Transition Protocols

This research explores the efficacy of different therapeutic alternatives in managing common gastrointestinal symptoms while reducing dependency on traditional medications.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.